Director of Business Development
GMP & Analytical Subcontractor Manager
The convention will take place at Estrel Hotel (Sonnenallee 225, 12057 Berlin, Germany):
Meet Dr. Valérie Kedinger & Dr. Pascale Belguise to discuss how to improve your transfection experiments. We will be happy to answer all your questions regarding transfection and to present you relevant products adapted to your research.
Our team will present a poster featuring in vivo-jetPEI®. You will find the abstract below:
in vivo-jetPEI, a non-viral vector of choice for nucleic acid delivery-based therapies
in vivo delivery of nucleic acids represents a novel promising approach for some medical applications such as gene and oligonucleotides therapy. in vivo-jetPEI, a cationic polymer-based reagent, is a very powerful non-viral vector to safely and easily deliver nucleic acids in vivo, through different routes of administrations. It forms stable complexes with the nucleic acid, protecting it from degradation and thus facilitating in vivo delivery. in vivo-jetPEI offers high performance in terms of efficiency, reproducibility and robustness. Following in vivo-jetPEI-mediated systemic delivery of nucleic acid, no induction of major pro-inflammatory cytokines and no increase in sera levels of hepatic enzymes is observed, making it a reliable and safe alternative to viral vectors that can elicit an immune response. Nowadays, in vivo-jetPEI is a widely used chemical reagent to deliver nucleic acids in animals and it has been selected as the delivery vector of choice in several drug development programs. For this purpose, Polyplus-transfection can supply preclinical grade as well as cGMP grade in vivo-jetPEI reagent. This reagent is used worldwide for a growing number of therapies based on plasmid or oligonucleotides delivery.
Our solutions for in vivo delivery
in vivo-jetPEI® is a powerful polymer based reagent used to deliver any nucleic acid to any animal model. in vivo-jetPEI® forms stable complexes with the nucleic acid, protecting it from degradation and thus facilitating in vivo delivery. With a proven track record (over 200 Publications), in vivo-jetPEI® has already been used to target a wide range of organs using various administration routes.
For GLP preclinical studies requiring the delivery of nucleic acids, Polyplus-transfection® supplies preclinical grade reagents that meet all the criteria for such studies. Polyplus-transfection® reagents are also perfectly suited for Cell Therapy Trials requiring a transfection step. Indeed, our reagents are manufactured in accordance with requirements for raw materials in Advanced Therapy Medicinal Product manufacturing for the generation of enhanced/modified cells.
in vivo delivery of nucleic acids represents a novel promising approach for some medical applications such as gene and oligonucleotides therapy. Polyplus-transfection® offers a cGMP grade in vivo-jetPEI® which is manufactured in compliance with applicable European Commission (EC) guide to Good Manufacturing Practices (GMP) and FDA requirements for clinical trials phase I to III. This reagent is used worldwide for a growing number of therapies based on nucleic acid delivery.